Big Blue Swim School Partners with Swim Angelfish to Offer Adaptive Swim Lessons
Big Blue Swim School announces its partnership with Swim Angelfish, whose specialized training equips Big Blue instructors with the skills to provide adaptive swim lessons at participating locations. Adaptive swim lessons are designed to make swim lessons accessible for children of all abilities, including those with physical, cognitive, and sensory needs.
According to the Centers for Disease Control and Prevention's recent Vital Signs study, pediatric drowning rates have been on the rise in recent years, and the Red Cross notes that children with autism are more likely to drown than neurotypical children. By offering these adaptive lessons, Big Blue aims to provide a safe and supportive environment for individuals to learn how to swim, improve their swimming skills, and gain water safety awareness.
'We truly believe that every child should have access to swim lessons,' says Chris DeJong, Founder and President of Big Blue Swim School, and five-time U.S. National Champion swimmer. 'As we embrace all that Autism Acceptance Month teaches us, to accept, celebrate and foster inclusivity, we're proud to offer adaptive swim lessons designed to meet each child's specific needs so they can learn in a way that is comfortable and safe for them.'
Big Blue Swim School's adaptive swim lesson instructors have been trained in Swim Angelfish's Swim Whisperers® method, specially designed to cater to children of all abilities, including those with sensory differences, challenges with motor skills, difficulty processing information, attention deficits, or any other condition that might physically or psychologically impede the process of learning to swim.
If you are looking for a trusted partner to build your child's confidence in the water and would like to learn more about Adaptive swim lessons, visit https://bigblueswimschool.com/programs/adaptive-swim-lessons.
About Big Blue Swim School
Big Blue Swim School offers an unparalleled swim lesson experience made easier and more effective by professional instructors, proprietary technology and curriculum, and family-friendly facilities. Big Blue creates and celebrates Big Moments in the pool which leads to kids learning they can achieve anything in life. Founded in 2009 by national champion swimmer Chris DeJong, Big Blue now has 45 pools and counting across the U.S. To learn more, visit www.BigBlueSwimSchool.com.
The Swim Whisperers® Certification is provided by Swim Angelfish®, experts in Adaptive Aquatics. This certification program equips swim instructors with specialized skills to teach individuals with ADHD, Autism, Down Syndrome or any type of emotional, physical or sensory challenge. These skills enable swim instructors to assess and identify challenges obstructing swim success, and teaches them how to tailor lessons to meet the specific needs of each individual. The Swim Whisperers® program empowers swim instructors to create a supportive learning environment for individuals with special needs to gain essential water safety and swim skills. To learn more visit
Trevelino/Keller
[email protected]
SOURCE: Big Blue Swim School
Copyright Business Wire 2025.
PUB: 03/31/2025 07:45 AM/DISC: 03/31/2025 07:46 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
31 minutes ago
- Business Wire
Archeus Technologies and Wisconsin Alumni Research Foundation Partner to Advance Radiopharmaceutical Therapy ART-101 into Clinical Development for Prostate Cancer
MADISON, Wis.--(BUSINESS WIRE)-- Archeus Technologies, a company developing multiple differentiated radiopharmaceutical therapies, and the Wisconsin Alumni Research Foundation (WARF), the patenting and licensing arm of the University of Wisconsin–Madison (UW), today announced a strategic collaboration to advance ART-101 – a promising receptor-based targeting molecule – into clinical development. ART-101 was discovered and developed at the Advanced Radiotheranostics Lab at UW–Madison, led by Dr. Reinier Hernandez, assistant professor of medical physics at the University of Wisconsin School of Medicine and Public Health. Aided by robust support from WARF through the WARF Accelerator, ART-101 has demonstrated enhanced pharmacology in preclinical studies, including significantly higher tumor uptake and retention relative to FDA-approved prostate cancer treatment Pluvicto ® (177Lu-PSMA-617). It has also shown superior pharmacokinetics, dosimetry and normal tissue toxicity profiles. Through a collaboration agreement with WARF, Archeus Technologies will lead Phase 1 clinical development of this asset with trial initiation planned for 2025. ART-101 is a next-generation prostate-specific membrane antigen (PSMA)-targeting small molecule. It is being evaluated as a radiopharmaceutical agent with the potential to deliver alpha-emitting isotopes with greater tolerability compared with current standards of care. 'With strong preclinical data supporting the continued development of ART-101, Archeus is eager to lead the evaluation of this novel candidate through first-in-human studies,' said Evan Sengbusch, Ph.D., chief executive officer of Archeus Technologies. 'Leveraging our team's proven experience ushering new radiopharmaceutical agents from concept through clinical translation, paired with our close collaboration with UW as a world-class radiopharmaceutical research organization, Archeus is uniquely positioned to progress ART-101 into the next stage of development. This asset adds to our Phase 1-ready portfolio of differentiated radiopharmaceutical therapies with the potential to provide curative responses to cancers that are particularly challenging to treat.' 'WARF is committed to investing in cutting-edge technologies and therapeutic candidates, like ART-101, that have significant potential to advance the theranostics landscape as well as treatment options for patients in need,' said Jeanine Burmania, senior director of intellectual property and licensing at WARF. 'Encouraging preclinical data suggest that ART-101 could help increase lifespan and be more effective in treating prostate cancer than current therapies. We're pleased to partner with Archeus Technologies to continue the development of this innovative asset and look forward to better understanding its role to potentially improve outcomes for prostate cancer patients.' ART-101 is compatible with multiple therapeutic isotopes, including actinium-225, lutetium-177 and terbium-161. When paired with these isotopes, preclinical data show that ART-101 provides significant potential benefit that could lead to improved outcomes for prostate cancer patients. About Archeus Technologies Archeus Technologies is a company developing differentiated radiopharmaceutical therapies for some of the most difficult-to-treat cancers. Starting with its Phase 1-ready therapeutic candidate, ARC-706, the company has assembled a growing pipeline of novel radiopharmaceutical therapy agents and companion diagnostic assets with the potential to provide curative responses to patients with advanced disease. Archeus is led by an executive team with proven radiopharmaceutical expertise and a demonstrated record of advancing innovative agents from discovery through clinical development. In addition, Archeus has a long-standing strategic collaboration with the University of Wisconsin-Madison (UW), a global leader in radiopharmaceuticals and theranostics. To learn more, visit About WARF Celebrating a century of service in 1925, the Wisconsin Alumni Research Foundation (WARF) patents and licenses discoveries from UW-Madison research, manages an investment portfolio generated from licensing and investment proceeds, and provides annual grants to the University of Wisconsin-Madison and the Morgridge Institute for Research to support further scientific investigation and research. By driving collaborations among researchers, investors, industry and entrepreneurs, WARF commercializes innovations from campus through various initiatives. WARF Accelerator improves the commercialization potential of university intellectual property through industry engagement and investment in proof-of-concept milestones to validate market potential, demonstrate commercial value and de-risk technology. WARF Therapeutics partners with UW-Madison and Morgridge Institute researchers employing an industry-focused approach to improve the value propositions of drug candidates. WARF Ventures is an early-stage venture fund that invests in startups based on UW/WARF technologies. Learn more at
Yahoo
2 hours ago
- Yahoo
Sanuwave Health Selected for Inclusion in Russell 2000® Index
EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, non-invasive wound care solutions, today announced, as part of the 2025 Russell indexes reconstitution, the Company's inclusion in the Russell 2000® Index. This will be effective after the U.S. market opens on June 30. In addition to the Russell 2000® Index, the Company is also expected to be included in the broader Russell 3000® Index and in the Russell Microcap® Index. The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest U.S. stocks as of April 30, ranked by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, results in automatic inclusion in either the Russell 1000® Index or the Russell 2000® Index, as well as the appropriate growth and value style indexes. FTSE Russell determines index membership primarily by objective, market-capitalization rankings and style attributes. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. As of June 2024, approximately $10.6 trillion in assets were benchmarked to the Russell U.S. indexes, which are maintained by FTSE Russell, a leading global index provider. For more information about the Russell indexes and the annual reconstitution process, please visit the 'Russell Reconstitution' section on the FTSE Russell website. About Sanuwave Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body's normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company's ability to manage its capital resources, competition and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement. Contact: investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:00 p.m. ET in New York City. Investors interested in arranging a meeting with company management during the conference should contact the Jefferies conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section on the Company's website at An archived replay of the webcast will be available for 60 days on the Company's website following the conference. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders. For more information, please visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company's ability to increase its net revenue from its products and the products of its subsidiaries; the Company's ability to commercialize its products and the products of its subsidiaries; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events. CONTACTS: Jack A. Khattar, President and CEOTimothy C. Dec, Senior Vice President and CFOSupernus Pharmaceuticals, Inc.(301) 838-2591 or INVESTOR CONTACT:Peter VozzoICR Healthcare(443) in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
